Jean-Marc LEMAITRE | Cellular Senescence Aging | Best Researcher Award

Published on by Cell Biologist

Dr. Jean-Marc LEMAITRE | Cellular Senescence Aging | Best Researcher Award

Dr. Jean-Marc LEMAITRE, INSERM UMR1183, France

Jean-Marc Lemaitre is a French biomedical researcher internationally renowned for his groundbreaking work on cellular reprogramming and aging reversal. Born on October 14, 1963, he is currently based at the Institute for Regenerative Medicine and Biotherapies (IRMB) in Montpellier, where he serves as co-director. His work has transformed the understanding of how aged cells can be rejuvenated, offering new hope for regenerative therapies. With a strong academic and clinical research background, Lemaitre has authored over 100 scientific articles and books on senescence, stem cells, and epigenetics. He is a board member of several scientific societies and journals, and continues to drive research at the frontier of aging science. Lemaitre is also a public science communicator and author, helping bridge cutting-edge biology with societal challenges related to aging. His passion for improving human health through innovative science places him at the forefront of biomedical research in France and globally.

Publication Profile:

Orcid

Google Scholar

Strengths for the Award:

  1. Pioneering Work in Aging Reversal
    Lemaitre was among the first scientists to show that senescent human cells can be rejuvenated, contributing significantly to cellular reprogramming and epigenetic longevity science.

  2. High-Impact Publications & Scientific Output
    Authored or co-authored over 100 scientific works, including in Nature Aging, Molecular Cell, Scientific Reports, and PNAS. His studies are cited globally in aging, regenerative medicine, and stem cell therapy.

  3. Institutional Leadership
    As Co-Director and Co-founder of IRMB, he manages a research institute with 180+ staff, positioning him as a key scientific leader in France.

  4. Scientific Recognition
    Member of scientific editorial boards and committees (e.g., Cells journal, Ligue Contre le Cancer), and board member of FSSCR, reflecting sustained leadership in the stem cell field.

  5. Translational & Interdisciplinary Impact
    His research has led to clinical insights in dermatology, osteoarthritis, and cardiology, demonstrating broad biomedical relevance beyond aging biology.

  6. Public Engagement and Science Communication
    Author of books like “Guérir la Vieillesse” and “Décider de son âge”, he bridges scientific knowledge with public interest in health and longevity.

Areas for Improvement:

  1. Expanded International Collaborations
    While Lemaitre collaborates across disciplines, further integration into global consortia or partnerships with biotech/pharma could amplify the translational value of his work.

  2. Visibility in Policy or Global Aging Initiatives
    Participation in policy advisory boards or international aging panels (e.g., WHO, UN Decade of Healthy Aging) would enhance his influence in shaping public health approaches to aging.

  3. Startups or Technology Transfer
    Commercialization of his discoveries (e.g., senescence therapies or reprogramming protocols) through startups or IP licensing would elevate his impact on innovation and real-world application.

Education:

Jean-Marc Lemaitre’s academic journey is rooted in molecular and developmental biology. He earned his DEA (Diplôme d’Études Approfondies) in Developmental Biology from Paris 6 University in 1991. His Doctorate (PhD) followed in 1995 from Paris 7 University, with research conducted at the esteemed Institut Jacques Monod in molecular and cellular biology. His early focus on the fundamental processes of cell development laid the groundwork for his future expertise in aging and regenerative medicine. In 2005, Lemaitre earned his Habilitation to Direct Research (HDR) from Montpellier University Medical School, a prestigious credential that allowed him to lead independent research projects. His educational path reflects a consistent and deep engagement with life sciences and a strong commitment to academic excellence. These milestones set the foundation for his leading role in cellular reprogramming and senescence-related research at both national and international levels.

Experience:

Jean-Marc Lemaitre has amassed over 30 years of professional experience in biomedical research, with a major focus on aging, senescence, and regenerative medicine. Since 2015, he has served as Co-Director and Cofounder of the IRMB (Institute for Regenerative Medicine and Biotherapies), which now houses over 180 researchers. His professional base is at the Saint Eloi Hospital in Montpellier, where he contributes both to translational research and clinical collaborations. Between 2014 and 2018, he held a Contrat d’Interface at CHU Montpellier, strengthening ties between research and healthcare. His pioneering work in cellular reprogramming earned international acclaim for demonstrating that senescent human cells could be rejuvenated using induced pluripotent stem cell (iPSC) technology. Lemaitre also plays leadership roles in research consortia such as the FHU REGENHAB and is an elected member of scientific committees, including the LIGUE Contre le Cancer du Septentrion. His experience is both deep and influential in shaping modern aging research.

Awards and Honors:

Jean-Marc Lemaitre has been recognized multiple times for his leadership and innovation in biomedical science. He was elected to the Scientific Committee of the LIGUE Contre le Cancer du Septentrion in 2019, reflecting his growing influence in translational medicine. In 2015, he co-founded and became Co-Director of IRMB, an institute now pivotal in stem cell and regenerative therapies. From 2014 to 2018, he was awarded a Contrat d’Interface at CHU Montpellier, enhancing integration between research and clinical practice. His work has also earned him positions on international editorial boards, including the “Cells” journal since 2020. In 2007, he co-founded and became a board member of the French Society for Stem Cell Research (FSSCR). These honors reflect not only the quality of his scientific contributions but also his dedication to mentorship, institution-building, and public engagement in science. He remains a key figure in aging and regenerative medicine globally.

Research Focus:

Jean-Marc Lemaitre’s research centers on cellular aging, senescence, and regenerative medicine. He is internationally renowned for demonstrating that aged or senescent human cells can be reprogrammed back to a pluripotent state—effectively reversing aging markers. His team has been at the forefront of identifying epigenetic mechanisms involved in aging and developing short reprogramming protocols to extend healthspan. He works extensively on senotherapeutics—interventions targeting the senescent cells that drive aging and disease—and has published seminal studies on skin aging, musculoskeletal regeneration, and systemic rejuvenation. Lemaitre is also a thought leader in developing blood-based epigenetic clocks to monitor aging and predict mortality. His integrative approach blends molecular biology, stem cell science, and translational medicine to uncover ways to slow or reverse aging processes. His work opens promising therapeutic avenues for treating age-related diseases, improving healthspan, and potentially redefining biological age through cellular reprogramming technologies.

Publications Top Notes:

  1. Disc-Derived iPSCs and Environmental Cues for Nucleus Pulposus Regeneration (Tissue Eng Part A, 2025)

  2. Blood-Based Epigenetic Clock for Intrinsic Capacity and Mortality (Nat Aging, 2025)

  3. Niacinamide and Hyaluronic Acid for Skin Aging: Clinical Correlation (Sci Rep, 2024)

  4. Décider de son âge (Book, 2024 – Allary Editions)

  5. Therapeutic Approaches Targeting Senescent Cells (Cells, 2023)

  6. Guérir la Vieillesse (Book, 2022 – Humensciences)

  7. Single Short Reprogramming Increases Healthspan (Aging, 2022)

  8. Epigenetic Mechanism Linking Early Reprogramming to Lifespan (Aging Cell, 2022)

  9. DNMT1-Driven 4D Genome Rewiring in Senescence (Molecular Cell, 2020)

  10. DNA Replication Timing as Marker in Progeroid Diseases (PNAS, 2017)

Conclusion:

Jean-Marc Lemaitre is a highly deserving candidate for the Best Researcher Award. He combines groundbreaking research in cellular aging and epigenetics with institutional leadership and public engagement. His work has transformed the understanding of biological aging, making him one of the most influential biomedical scientists in Europe in this domain. The award would not only recognize his scientific excellence but also highlight the increasing importance of healthy aging, regenerative medicine, and cellular rejuvenation in modern medicine.

Chun Yan | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Chun Yan | Stem Cell Research | Best Researcher Award

Dr. Chun Yan, Department of Thoracic Surgery, Zhongshan Hospital of Xiamen University, China

Dr. Yan Chun is an Attending Physician at the School of Medicine/Zhongshan Hospital, Xiamen University. With a solid foundation in clinical medicine and surgery, Dr. Chun brings over a decade of experience in thoracic oncology and AI-driven medical research. After earning a Bachelor’s degree from Fujian Medical University, he pursued his Master’s in Surgery at Shanghai Jiao Tong University. Since 2018, Dr. Chun has contributed significantly to clinical practice, medical innovation, and academic research. His current focus includes AI-assisted diagnosis, radiogenomics, and the biomechanics of thoracic surgery. A recognized member of the Minimally Invasive Thoracic Oncology Committee under the Fujian Primary Health Association, he has received multiple accolades for his pioneering work in esophageal cancer therapy. Dr. Chun’s commitment to precision medicine and integration of AI in healthcare highlights his suitability for prestigious research honors and positions him as a leader in translational medical research in China.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Strong Academic Foundation: Dr. Yan Chun holds a Master’s degree in Surgery from Shanghai Jiao Tong University and a Bachelor’s degree in Clinical Medicine, ensuring a robust foundation in both research and clinical practice.

  2. Innovative Research: He leads and participates in cutting-edge projects that integrate AI, radiogenomics, and biomechanical modeling, reflecting a multidisciplinary and forward-thinking approach.

  3. Recognized Excellence: His work has been honored with regional innovation and scientific progress awards, demonstrating tangible contributions to thoracic oncology.

  4. Clinical Expertise: With 7+ years of medical experience, including as an attending physician, he bridges practical medicine with impactful research.

  5. Leadership Role: Serving on a professional committee in minimally invasive thoracic oncology highlights his thought leadership within his specialty.

🧠 Areas for Improvement:

  1. Expanded Publication Record: While impactful, Dr. Chun’s publication portfolio would benefit from a broader presence in international, high-impact journals to boost academic visibility.

  2. International Collaboration: Engaging in cross-border research partnerships could enhance both innovation scope and influence.

  3. Grant Scale: Existing grants are modest in size. Applying for national-level or larger competitive grants could support more ambitious projects.

  4. Mentorship and Training: Documenting roles in mentoring junior researchers or medical students would strengthen his academic leadership profile.

🎓 Education:

Dr. Yan Chun’s academic journey began with a Bachelor of Clinical Medicine (MBBS) from Fujian Medical University (2010–2015), where he gained fundamental clinical knowledge and medical training. He then advanced his specialization in surgery by completing a Master of Surgery (MS) at Shanghai Jiao Tong University (2015–2018), one of China’s top medical institutions. His education emphasized evidence-based clinical practice, surgical skills, and research methodology. During his postgraduate studies, he was actively involved in academic projects, laying a strong foundation for his later research in thoracic oncology and artificial intelligence in medicine. This robust educational background equips him with interdisciplinary expertise, bridging clinical medicine, surgical techniques, and research innovation—especially in radiogenomics and perioperative therapies for esophageal cancer. His training reflects both academic rigor and a forward-looking approach to integrating emerging technologies with healthcare delivery, making him well-prepared to drive impactful research initiatives.

💼 Experience:

Dr. Yan Chun has held progressive roles at Zhongshan Hospital, Xiamen University since 2018. Starting as a Physician (2018–2023), he delivered comprehensive clinical care while engaging in translational research projects. Since July 2023, he has been serving as an Attending Physician, contributing to surgical excellence and AI-assisted diagnostic strategies in thoracic oncology. His hands-on clinical experience is complemented by leadership in grant-funded research, particularly in predictive modeling and biomechanics. Dr. Chun’s involvement in multi-disciplinary teams, collaborations with AI scientists, and contributions to surgical innovation have advanced the care standards in thoracic surgery. He has also actively contributed to institutional and provincial-level scientific programs, showcasing his capability in both practical medicine and medical research. His work stands at the intersection of clinical practice and innovation, and he remains committed to improving outcomes for patients with complex thoracic conditions through precision diagnostics and minimally invasive techniques.

🏅 Awards and Honors:

Dr. Yan Chun has received multiple accolades recognizing his innovative contributions to thoracic oncology and surgical AI. His project, “AI-Assisted Precision Perioperative Individualized Therapy for Esophageal Cancer”, was selected as one of the Top Ten Innovations of the Year by the Xiamen Hospital Association, highlighting its impact on personalized medicine. Another landmark project, “Precision Diagnosis and Treatment Paradigm for Esophageal Squamous Cell Carcinoma Driven by AI and Multi-Omics Integration”, earned him the Third Prize for Scientific and Technological Progress from the Fujian Anti-Cancer Association, underscoring his leadership in advanced cancer care. His awards reflect not only clinical innovation but also excellence in multi-disciplinary research. These honors are a testament to his ability to bridge clinical needs with technological advancements, demonstrating vision, technical skill, and translational impact. They position him as a high-impact researcher contributing meaningfully to China’s evolving healthcare landscape.

🔬 Research Focus:

Dr. Yan Chun’s research is primarily centered on the integration of artificial intelligence, radiogenomics, and thoracic oncology. He leads a government-funded project investigating deep learning-based predictive models for lymph node metastasis and prognosis in esophageal cancer, leveraging imaging-genomics to improve pre- and post-operative decision-making. He also contributed to biomechanical analysis of the NUSS procedure for pectus excavatum, applying finite element modeling to improve surgical outcomes. His work merges clinical data science, image processing, and genomics, aiming to build personalized treatment pathways and enhance minimally invasive approaches. Dr. Chun’s interdisciplinary approach reflects a deep understanding of both computational technologies and real-world clinical challenges. His ambition is to develop AI-powered platforms that augment oncological diagnostics and optimize surgical interventions. Through a combination of hands-on experience and research rigor, he is at the forefront of precision medicine in thoracic surgery, striving for innovation that is both data-driven and patient-centered.

📚 Publications Top Notes:

📖 Association between per- and polyfluoroalkyl substances exposure and prevalence of chronic obstructive pulmonary disease: The mediating role of serum albumin – Science of the Total Environment, 2024 🌱🫁

🧾 Conclusion:

Dr. Yan Chun demonstrates exceptional promise and maturity as a clinical researcher whose work lies at the confluence of AI, precision medicine, and thoracic surgery. His contributions to the diagnosis and treatment of esophageal cancer through radiogenomic modeling and minimally invasive techniques are both innovative and clinically meaningful. Backed by professional recognition and a strong clinical research ethic, Dr. Chun is a worthy candidate for the Best Researcher Award. With expanded international presence and high-impact publications, he is poised to become a leading figure in the global thoracic oncology research community.

Zhaowei Feng | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Dr. Zhaowei Feng | Stem Cell Research | Best Researcher Award

Dr. Zhaowei Feng, The Second Affiliated Hospital of Xuzhou Medical University, China

Zhaowei Feng is a dedicated biomedical researcher specializing in neurobiology and pharmacology, currently serving as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. With a solid academic foundation and a passion for neuroscience, Feng has made significant contributions to understanding mechanisms of neuroprotection and demyelination. His research spans neurodegenerative disease models such as multiple sclerosis and neonatal hypoxia-ischemia, utilizing molecular and cellular biology tools. Known for his collaborative nature and scientific rigor, Feng has co-authored multiple peer-reviewed articles in prestigious journals and has played pivotal roles in various national and municipal-level research projects. He is particularly recognized for co-first authorship in several studies, reflecting leadership in experimental design and data analysis. His growing influence in the field is further supported by ongoing funded projects and a research trajectory aimed at translational outcomes. Feng is committed to continuing impactful research that bridges bench science with clinical applications.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Strong Research Focus in Neurobiology 🧠
    Zhaowei Feng has a consistent and impactful research portfolio in neurobiology, particularly in myelination, ischemia-reperfusion injury, and glutamate signaling. His work is highly relevant in addressing diseases like multiple sclerosis and neonatal hypoxia-ischemia encephalopathy.

  2. Publications in High-Impact Journals 📚
    He has co-authored several peer-reviewed journal articles in reputable journals such as Phytomedicine, Pharmacology, Oncology Reports, and Frontiers. His contributions as co-first author in multiple papers reflect significant involvement in study design and experimentation.

  3. Independent Researcher Role 🧪
    He currently serves as a Principal Investigator for a municipal-level research project funded by the Xuzhou Health Commission, demonstrating trust in his leadership and research direction.

  4. Multidisciplinary Expertise 🔬
    His research integrates pharmacology, molecular biology, and neuroscience, covering diverse mechanisms like PPARγ signaling, SUMOylation, and ferroptosis, which enhances translational potential.

  5. Rapid Academic Growth 🚀
    Transitioning quickly from a Master’s student (2019–2022) to Assistant Researcher and PI (since 2022) shows a fast-tracked academic trajectory.

⚠️ Areas for Improvement:

  1. Need for More First-Author and Corresponding-Author Papers ✍️
    While co-first authorship is commendable, a stronger emphasis on sole first or corresponding authorship in future publications would establish more scientific independence.

  2. Limited Recognition at National Level 🏅
    Most current funding and achievements are at the municipal level. Applying for national or international grants (e.g., NSFC, NIH) would elevate his research profile.

  3. Postdoctoral Training or Collaboration Abroad 🌍
    Gaining international experience or collaborating with global research centers could broaden perspectives and techniques, increasing citation impact and networking.

  4. More Diversified Research Outputs 📊
    Exploring patents, clinical trials, or translational research outcomes could further demonstrate innovation and application potential.

🎓 Education:

Zhaowei Feng began his academic journey in the biological sciences at Xuzhou Medical University, where he earned his Bachelor’s degree between 2014 and 2018. He further pursued a Master’s degree in Neurobiology at the same institution from September 2019 to July 2022. His graduate studies were marked by an intensive focus on neurodegenerative mechanisms, including demyelination and neuroinflammation, with particular attention to cuprizone-induced and ischemia-reperfusion mouse models. His research also explored glutamate transport regulation, the PPARγ pathway, and oligodendrocyte differentiation. His educational foundation not only provided him with technical proficiency in experimental neuroscience but also cultivated a strong understanding of translational biomedical research. Through rigorous coursework, laboratory experience, and thesis writing, Feng developed a robust academic profile that seamlessly transitioned into his research career. His educational journey reflects consistent dedication and a clear trajectory towards clinical and experimental neurobiology.

🧪 Experience:

Since September 2022, Zhaowei Feng has been working as an Assistant Researcher at The Second Affiliated Hospital of Xuzhou Medical University. His role involves leading preclinical studies, managing collaborative projects, and mentoring junior researchers. Feng has also served as Principal Investigator on a municipal-level research grant focusing on blood-brain barrier damage post-transplantation. He actively participates in multiple interdisciplinary studies involving neurodevelopment, myelination, and pharmacological interventions. Prior to his current role, his Master’s research provided hands-on experience with animal models, molecular techniques, and data analysis in neurobiology. Feng has authored or co-authored numerous research papers, some as co-first author, contributing significantly to study design and execution. He is also involved in translational research projects that aim to bridge laboratory findings with clinical therapies. His work ethic, attention to detail, and innovative approach make him a valuable contributor to the field of neurobiological research.

🏅 Awards and Honors:

Zhaowei Feng has been recognized for his scientific contributions through both academic and research-oriented accolades. Notably, he is the recipient of a research grant from the Xuzhou Municipal Health Commission (Project No. XWKYHT20230029), focusing on cerebral ischemia-reperfusion and blood-brain barrier injury. Though early in his professional career, his selection as Principal Investigator on this project signifies trust in his leadership and expertise. Several of his publications in high-impact journals list him as co-first author—an honor that highlights his equal contribution in rigorous experimental work. While he has yet to receive national awards such as from the Natural Science Foundation, his steady academic output and funded research projects mark a strong trajectory. His growing publication record and role in significant studies position him as a rising talent in the biomedical field. Future honors are likely as his research continues to address key questions in neuroscience and pharmacology.

🔬 Research Focus:

Zhaowei Feng’s research centers on neuroprotection, demyelination, and neuroinflammation, with a particular focus on the mechanisms underlying multiple sclerosis, ischemic brain injury, and neonatal encephalopathy. His studies often employ animal models such as cuprizone-induced demyelination and hypoxia-ischemia to explore therapeutic targets. Feng is particularly interested in the regulation of oligodendrocyte differentiation and the role of glutamate transporters, signaling molecules like PPARγ, and pathways involving Wnt/β-catenin and SUMOylation. Additionally, he has investigated compounds such as diosgenin and alpha-asaronol for their neuroprotective and remyelination-promoting effects. His work also extends into cancer biology, with studies on ferroptosis and protein regulation in squamous cell carcinoma. By integrating molecular biology, pharmacology, and neurodevelopmental research, Feng aims to contribute to the discovery of new treatments for central nervous system disorders. His current and future research is geared toward translational medicine that bridges laboratory science with clinical applications.

📚 Publication Top Notes:

  1. 🧠 Alpha-Asaronol Alleviates Dysmyelination by Enhancing Glutamate Transport via PPARγ-GLT-1 Signaling in Neonatal Hypoxia-Ischemia (Pharmacology, 2022)

  2. 🧬 C1q Inhibits Differentiation of Oligodendrocyte Progenitor Cells via Wnt/β-Catenin Signaling (Biomedicine & Pharmacotherapy, 2023)

  3. 🧪 Alpha-Asaronol Promoted OPC Differentiation and Improved Myelination as a PPARγ Activator (Frontiers, 2023)

  4. 🧫 Diosgenin Promoted OPC Differentiation by Blocking GLUR2/GAPDH Interaction in Pilocarpine-Induced Epilepsy Rats (Phytomedicine, 2025)

  5. 🧬 Netrin-4 Mediates Piezo1 Inactivation and YAP Signaling Alleviation in Cerebral Ischemia-Reperfusion (Oncology Reports)

  6. 🔬 SENP1 Inhibits Ferroptosis and Promotes Head and Neck Squamous Cell Carcinoma by Regulating ACSL4 Protein (Molecular Oncology, 2023)

  7. 🧪 SUMO1-Mediated Stabilization Enhances Protein Function in Neuroinflammatory Models (Unspecified Journal)

  8. 🧠 Signaling Activation in a Cuprizone-Induced Mouse Model of Multiple Sclerosis (Unspecified Journal)

📌 Conclusion:

Zhaowei Feng is a highly promising early-career researcher with a clear scientific focus, a growing publication record, and demonstrated ability to lead independent research. His work addresses critical challenges in neurobiology and pharmacology, making a tangible impact in both experimental and translational medicine. With continued progression—especially toward national-level recognition and senior authorship—he has the potential to become a leader in his field.

ALINE TAKEJIMA | Tissue engineering | Women Researcher Award

Published on by Cell Biologist

Dr. ALINE TAKEJIMA | tissue engineering | Women Researcher Award

Dr. ALINE TAKEJIMA, pontificia universidade catolica do parana, Brazil

Dr. Aline Luri Takejima is a physician-scientist from Brazil, specializing in regenerative medicine and wound healing. She holds an MD and a PhD in Health Sciences from the Pontifical Catholic University of Paraná (PUCPR), where she currently conducts postdoctoral research. With a focus on biological therapies involving the amniotic membrane, Wharton’s jelly, and mononuclear stem cells, Dr. Takejima has published in multiple high-impact scientific journals. Her research aims to develop novel regenerative strategies to treat complex wounds and enhance tissue repair. As an active member of PUCPR’s Wound Healing Research Group and the Brazilian Society of Plastic Surgery, she combines scientific rigor with clinical insight to bridge bench-to-bedside innovation. Her academic contributions are guided by a translational approach, offering promising avenues for future clinical applications in tissue engineering.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Focused Research Excellence:
    Dr. Takejima’s work on biological scaffolds and stem cells in wound healing is both innovative and clinically relevant. Her studies using amniotic membrane, Wharton’s jelly, and bone marrow mononuclear cells show promising regenerative outcomes in preclinical models.

  2. Research Productivity:
    With 9 peer-reviewed journal articles in high-quality platforms (e.g., Biomedicines, Tissue Barriers, Annals of Biomedical Engineering), she demonstrates consistent academic output in her field.

  3. Translational Impact:
    Her research bridges basic science and clinical practice, aiming to provide regenerative solutions for patients with chronic wounds and cardiac damage.

  4. Collaborative Engagement:
    Active participation in a multidisciplinary wound healing research group, contributing to cross-functional scientific advancements.

  5. Recognition Potential:
    As a young, emerging woman researcher in biomedical sciences, she stands as a role model for future female scientists in Latin America and beyond.

🔧 Areas for Improvement:

  1. Intellectual Property & Innovation:
    No patents filed yet; transitioning her research into patentable therapies or commercial applications would increase its societal and economic impact.

  2. Leadership Roles:
    While active in research, taking on editorial or scientific leadership positions would enhance her academic visibility and influence.

  3. Internationalization:
    She would benefit from developing international collaborations or fellowships to diversify her research scope and increase global reach.

  4. Industry Engagement:
    Engaging in consultancy or biotech partnerships can further the translational impact of her regenerative strategies.

🎓 Education:

Dr. Takejima’s educational journey began with a Doctor of Medicine (MD) degree from the Pontifical Catholic University of Paraná (PUCPR), Brazil. Her passion for research led her to pursue a Doctorate (PhD) in Health Sciences/Medicine, also at PUCPR. Her doctoral thesis focused on the use of biologically active materials such as the amniotic membrane and stem cells to enhance wound healing. Throughout her academic training, she demonstrated a strong commitment to translational medicine by integrating basic science with clinical practice. During her PhD, she engaged in experimental models involving stem cell therapy and tissue engineering, which laid the groundwork for her current postdoctoral research. Her educational path reflects both depth and specialization in the biomedical sciences, particularly in regenerative medicine and cellular therapies.

💼 Experience:

Dr. Aline Takejima has over a decade of experience in medical and scientific fields, balancing her role as a physician with that of a postdoctoral researcher. Her clinical background informs her research, particularly in areas of wound healing and regenerative medicine. At PUCPR, she contributes to the Wound Healing Research Group, where she is involved in designing and conducting animal model studies to test the effects of biomaterials and stem cells. Her multidisciplinary research integrates immunology, histopathology, and molecular biology. With nine peer-reviewed publications and participation in collaborative research, she has become a respected contributor to the field. Though early in her research career, her trajectory shows a steady rise, marked by evidence-based outcomes and a commitment to innovation. Her goal is to bridge clinical challenges with regenerative solutions that can be implemented in real-world medical practice.

🔬 Research Focus:

Dr. Takejima’s research focuses on regenerative strategies for wound healing, utilizing biomaterials and stem cells. Her work primarily explores the application of amniotic membrane, Wharton’s jelly, and bone marrow-derived mononuclear stem cells in treating complex or chronic skin wounds. Using experimental models in rats and rabbits, she evaluates histological recovery, inflammation modulation, and tissue regeneration. A significant aspect of her research is understanding how these materials promote healing through paracrine effects rather than direct integration, offering a safer and scalable pathway to clinical application. Additionally, her work extends to cardiac and tracheal tissue repair, emphasizing the versatility of these regenerative approaches. The translational nature of her research bridges laboratory discoveries with potential bedside applications, positioning her at the forefront of cellular therapy and biomaterials science.

📚 Publications Top Notes:

  1. 🧠 Wharton’s Jelly Bioscaffolds Improve Cardiac Repair with Bone Marrow Mononuclear Stem Cells in Rats – Journal of Functional Biomaterials, 2025

  2. 🧫 The effects of decellularized amniotic membrane and Wharton’s jelly on the healing of experimental skin wounds in rats – Tissue Barriers, 2025

  3. ❤️ Bone-marrow mononuclear cells and acellular human amniotic membrane improve global cardiac function… – Anais da Academia Brasileira de Ciências, 2024

  4. 🫁 Tracheal regeneration with acellular human amniotic membrane and 15d-PGJ2 nanoparticles in rabbits – Anais da Academia Brasileira de Ciências, 2023

  5. 🧬 Acellular Biomaterials + Autologous Stem Cells Improve Wound Healing via Paracrine Effects – Biomedicines, 2023

  6. 💉 Decellularized Amniotic Membrane Solubilized with Hyaluronic Acid in Wound Healing – Annals of Biomedical Engineering, 2022

  7. 🧪 Role of Mononuclear Stem Cells and Decellularized Amniotic Membrane in Skin Wounds – Tissue Barriers, 2022

  8. 🏥 Trauma hepático: epidemiologia de cinco anos… – Revista do Colégio Brasileiro de Cirurgiões, 2008

🧾 Conclusion:

Dr. Aline Luri Takejima is an outstanding candidate for the Women Researcher Award. Her academic profile demonstrates a strong foundation in regenerative medicine with significant contributions to wound healing research. Her commitment to applying biological therapies in clinical contexts shows both depth and innovation. As a woman scientist in a competitive field, she exemplifies leadership, dedication, and potential. With further growth in global engagement and innovation strategy, Dr. Takejima is poised to become a future leader in regenerative biomedical research.

Hongliang Xin | Tissue Engineering Regeneration | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Hongliang Xin | Tissue Engineering Regeneration | Best Researcher Award

Prof. Dr. Hongliang Xin, Nanjing Medical University, China

Professor Hongliang Xin is a distinguished pharmaceutical scientist at Nanjing Medical University, China. After earning his PhD from Fudan University in 2011, he joined Nanjing Medical University and rapidly rose through academic ranks, becoming a full professor by 2020. His international experience includes a research fellowship at North Carolina State University (2015–2016), enriching his global academic outlook. Professor Xin has made significant contributions in drug delivery, particularly for brain disorders and cancer. His work on biomimetic nanoparticles and dual-targeting systems has been widely recognized, with several of his publications cited hundreds of times. He is a recipient of the Jiangsu Outstanding Research Award and has contributed to translational science through interdisciplinary collaboration. Committed to innovation in intelligent drug delivery, Professor Xin continues to push boundaries in nanomedicine. His dedication and impactful research make him a strong candidate for the Best Researcher Award.

Publication Profile: 

Google Scholar

✅ Strengths for the Award:

  1. Innovative Research in Drug Delivery
    Prof. Xin has led pioneering work in cellular biomimetic drug delivery systems and brain-targeted therapies, particularly utilizing Angiopep-conjugated and ROS-responsive nanoparticles. His research shows deep innovation in crossing the blood-brain barrier — a major challenge in neuroscience and oncology.

  2. Strong Publication Record
    He has authored multiple high-impact publications in top-tier journals such as Biomaterials, ACS Nano, and Advanced Materials. Several of these works have citations exceeding 300–400, indicating significant influence in the scientific community.

  3. International Research Exposure
    His experience as a visiting scholar at North Carolina State University reflects a global approach to science, enhancing both the breadth and depth of his research collaborations.

  4. Consistent Career Growth
    From lecturer to professor within a decade, Prof. Xin’s steady academic rise reflects both merit and dedication.

  5. Recognition and Awards
    Recipient of the Jiangsu Outstanding Research Award, validating his contributions at the provincial and national level.

⚙️ Areas for Improvement:

  1. Clinical Translation
    While preclinical research is robust, moving towards clinical trials or commercial partnerships would greatly strengthen the translational impact of his work.

  2. Leadership in International Consortia
    Increased participation or leadership in global research initiatives, conferences, or consortia could further elevate his visibility and impact internationally.

  3. Cross-Disciplinary Outreach
    Expanding collaborations into neuropsychology, regenerative medicine, or pharmaceutical industry applications could broaden the application of his delivery systems.

🎓 Education:

Hongliang Xin completed his doctoral studies in Pharmacy at Fudan University in 2011, one of China’s most prestigious universities. His academic journey was grounded in pharmaceutical sciences, focusing on drug delivery systems and nanotechnology-based therapies. During his PhD, he laid the foundation for his future research in targeted therapy and biomimetic materials. Post-PhD, he expanded his academic training internationally as a visiting scholar at North Carolina State University in the United States (2015–2016). This exposure to global research trends and interdisciplinary approaches further honed his expertise. The integration of chemical engineering, pharmacology, and nanotechnology into his educational training has allowed him to develop innovative and effective therapeutic strategies for brain-targeted drug delivery. His education has not only equipped him with strong technical skills but also with a visionary approach to translational medicine.

🧪 Experience:

Dr. Hongliang Xin began his academic career as a lecturer at Nanjing Medical University’s School of Pharmacy in 2011. He was promoted to Associate Professor in 2015 and became a Full Professor in 2020. Over the years, he has built a robust research program in nanomedicine and drug delivery, leading multiple funded projects and mentoring graduate students. His one-year tenure as a visiting scholar at North Carolina State University provided him international collaborative opportunities, boosting his cross-disciplinary competence. Professor Xin has published extensively in high-impact journals such as Biomaterials, ACS Nano, and Advanced Materials. He is also a recognized leader in translational drug delivery platforms, specifically for brain diseases and cancer. His extensive teaching, grant acquisition, and collaborative research background reflect both academic maturity and innovation. His professional journey exemplifies excellence, persistence, and a global perspective on healthcare research.

🔬 Research Focus:

Professor Hongliang Xin’s research centers on cellular biomimetic drug delivery systems and intelligent therapeutic strategies for brain diseases such as glioblastoma and ischemic stroke. His work integrates polymer chemistry, pharmacokinetics, and molecular targeting to design nanoparticles that can cross the blood-brain barrier with precision. A key innovation in his research is the use of Angiopep-conjugated polymers and ROS-responsive carriers to ensure site-specific and safe drug delivery. His dual-targeting PEG-PCL nanoparticle system has shown remarkable results in preclinical models of brain cancer, while his transcutaneous immunotherapy approach enhances anti-tumor immunity. Professor Xin’s focus also extends to thrombolytic delivery systems, neuroprotectants, and engineered nano-platelets for hematologic malignancies. With over a decade of focused work, his lab continues to address clinical challenges in oncology and neurology, aiming to translate nanoscale innovations into real-world therapeutics.

📚 Publications Top Notes:

  1. 🧠💊 Angiopep-conjugated PEG-PCL nanoparticles as dual-targeting system for brain glioma

  2. 🧬🛡 Anti-glioblastoma efficacy of paclitaxel-loaded Angiopep-conjugated PEG-PCL nanoparticles

  3. 💉🧫 Synergistic transcutaneous immunotherapy for checkpoint inhibitor delivery and tumor response

  4. 🧠🎯 2-deoxy-D-glucose functionalized PEG-PTMC nanoparticles for glioma targeting

  5. 🧠⚡ Boronic ester-dextran polymer nanoparticles responsive to ROS for stroke therapy

  6. 🧫🩸 Nano-platelets for enhanced treatment of multiple myeloma and thrombus

  7. 🧠🧬 Site-specific delivery of thrombolytics and neuroprotectants for ischemic stroke

  8. 🧠🧪 Brain targeting mechanism of Angiopep-conjugated PEG-PCL nanoparticles

  9. 🧠💉 Dual-targeted nanocarrier for treatment of brain ischemic stroke

  10. 💊🧠 Integrin-mediated PEG-PTMC nanoparticles for solid tumor penetration and paclitaxel delivery

🧾 Conclusion:

Professor Hongliang Xin is a highly qualified and impactful researcher whose contributions in intelligent, targeted drug delivery—especially for brain diseases—are both scientifically innovative and socially relevant. His work bridges critical gaps in nanomedicine and therapeutic targeting, and his publications are widely cited, reflecting broad recognition. With strategic focus on clinical translation and deeper global engagement, his already excellent profile could reach even greater heights.

Yang Liu | Cell Migration Studies | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Yang Liu | Cell Migration Studies | Best Researcher Award

Prof. Dr. Yang Liu, Taiyuan University of Technology Institute of Biomedical Engineering CHINA, China

Dr. Yang Liu is an Associate Professor at the Institute of Biomedical Engineering, Taiyuan University of Technology, China. Since joining in 2013, Dr. Liu has focused on biomechanics, particularly the mechanical mechanisms involved in skin tissue damage and healing processes during traumatic events like burns and radiotherapy. Her interdisciplinary work bridges molecular, cellular, and tissue-level studies to better understand the interplay between mechanical factors and skin regeneration. Her research also extends into the development and structural optimization of biomedical materials such as tissue-engineered skins and advanced dressings. Dr. Liu has led several research and teaching reform projects, obtained a patent transformation, and contributed to national and provincial-level scientific investigations. Her innovative work in tissue engineering and skin trauma treatment continues to contribute significantly to biomedical science and material engineering.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Specialized Expertise
    Dr. Liu focuses on biomechanics in disease development, particularly related to cutaneous trauma (e.g., burns, radiotherapy), a niche but critical area in biomedical engineering.

  2. Material Innovation
    Her work in developing tissue-engineered skin and antibacterial dressings demonstrates applied innovation with potential clinical relevance.

  3. Project Leadership
    Successfully led and participated in multiple competitive research projects funded by national and provincial bodies, indicating trust in her scientific vision and capabilities.

  4. Research Productivity
    Though early in recognition, Dr. Liu has already co-authored several peer-reviewed journal articles in reputable publications like Scientific Reports and Placenta, which reflect growing academic contribution.

  5. Translational Research
    Her involvement in a patent achievement transformation shows a commitment to moving research beyond the lab into real-world applications.

🔧 Areas for Improvement:

  1. Citation Impact and Indexing
    The provided articles currently have 0 citations, and there is no citation index or h-index reported. Increasing publication visibility and citation impact should be a future focus.

  2. Global Recognition and Collaboration
    There is no mention of international collaboration, editorial roles, or professional memberships, which would enhance credibility and reach.

  3. Documented Industry Linkages
    Despite some project engagement with enterprises, more evidence of sustained industry partnerships or commercialization success would strengthen the application.

  4. Books, Patents, and Conferences
    Absence of published books, patents in process, or keynote roles in international conferences limits the academic portfolio breadth.

🎓 Education:

Although specific degree details are not listed, Dr. Yang Liu has built a strong academic foundation that supports her expertise in biomedical engineering and biomechanics. Her academic journey is closely aligned with her professional role at Taiyuan University of Technology, which is known for its technical research capabilities. Dr. Liu’s knowledge spans skin tissue biology, mechanical trauma, and biomedical materials science, indicating a background that likely includes degrees in biomedical engineering, bioengineering, or a related field. Her educational experience has equipped her with the skills necessary to conduct high-level research in skin regeneration, materials science, and tissue biomechanics. Additionally, her active participation in national scientific projects and her leadership in academic innovation at the university level point to rigorous formal training and ongoing academic development.

🧪 Experience:

Dr. Yang Liu has over a decade of professional experience in biomedical research since joining the Taiyuan University of Technology in 2013. Her work has revolved around exploring the mechanical and biological factors involved in traumatic skin injury and healing. She has successfully led and contributed to multiple projects, including those funded by the National Natural Science Foundation of China and enterprise collaborations. In addition to her scientific contributions, she has also directed teaching reform projects and a patent transformation, highlighting her dual commitment to both research and education. Her experience includes a strong focus on interdisciplinary collaboration across biology, materials science, and mechanical engineering. This breadth of experience has allowed her to develop innovative biomedical materials, such as tissue-engineered skin and functional skin dressings, aimed at improving clinical treatment outcomes for burn injuries and other trauma-related skin conditions.

🔬 Research Focus:

Dr. Yang Liu’s research centers on the biomechanics of skin tissue damage and healing, with an emphasis on cutaneous trauma from burns and radiotherapy. Her work investigates how mechanical forces impact skin at multiple biological levels—molecular, cellular, tissue, and animal models. A major portion of her research explores biomedical material innovation, particularly tissue-engineered skin, skin dressings, and antibacterial materials. She is particularly focused on understanding how structural and mechanical properties of these materials can improve therapeutic outcomes. Dr. Liu also studies oxidative stress, cell migration, and protein responses under mechanical pressure, making her work crucial to trauma therapy and regenerative medicine. With a patent transformation and multiple research projects to her credit, her research is positioned at the intersection of engineering innovation and clinical application, aiming to reduce complications in skin trauma treatment and enhance recovery efficiency through scientifically engineered materials.

📚 Publications Top Notes:

  1. 🧴🧬 Preparation and characterization of nano-silver/graphene oxide antibacterial skin dressing – Scientific Reports, 2025

  2. 🔬⛽ Experimental study on liquid products and pore structure characteristics of anthracite saturated by supercritical CO₂ – Gas Science and Engineering, 2025

  3. 🧠💥 The regulatory role of the nuclear scaffold protein Emerin on the migration of amniotic epithelial cells and oxidative stress in a pressure environment – Placenta, 2025

  4. 🛠️🔥 Annealing Response of Cold-rolled Ti₂AlNb Based Alloy Foil in Different Phase Regions – Tezhong Zhuzao Ji Youse Hejin (Special Casting and Nonferrous Alloys), 2025

📝 Conclusion:

Dr. Yang Liu shows significant promise as a biomedical researcher, with a clear, focused research trajectory, practical outputs (materials for skin regeneration), and consistent project engagement at institutional and national levels. While her global visibility and citation metrics are currently limited, her research has high translational potential in trauma medicine and biomedical materials, making her a strong emerging contender for the Best Researcher Award—especially under a category recognizing early- to mid-career researchers with impactful applied science work.

Zhi Guo | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Dr Zhi Guo | Stem Cell Research | Best Researcher Award

Prof. Dr Zhi Guo | Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital | China

Dr. Zhi Guo is a distinguished expert in hematology with over 25 years of clinical and academic experience. Currently serving as Director, Academic Leader, Chief Physician, and Professor at the Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, he has been instrumental in advancing hematologic malignancy treatments in China. With extensive expertise in hematopoietic stem cell transplantation, Dr. Guo has successfully performed more than 1,300 transplant cases. He began his career at the PLA Army General Hospital, serving there for nearly two decades before transitioning to his current role. A prolific researcher, he has authored over 10 peer-reviewed publications and five books, contributing substantially to the understanding of CAR-T therapy, gut microbiota, and transplantation immunology. He is an active member of major national and international hematology associations and plays a vital role in formulating clinical consensus and guidelines in China.

publication profile:

Scopus

Strengths for the Award:

Dr. Zhi Guo exemplifies the qualities of an outstanding medical researcher and clinician. With nearly 25 years of clinical experience in hematology and over 20 years in hematopoietic stem cell transplantation, he stands out as a national leader in this field. His performance of more than 1,300 transplants, along with a strong academic footprint, including 10 SCI-indexed publications in 2024–2025, demonstrates both depth and innovation in his research. He has also contributed to national expert consensus and clinical guidelines, particularly in CAR-T therapy and intestinal microecology. Dr. Guo’s leadership roles across national academic committees and his active membership in the American Society of Hematology further highlight his international impact and collaborative influence.

Areas for Improvement:

While Dr. Guo’s achievements in clinical practice and research are significant, opportunities exist to increase global visibility by expanding his research collaborations internationally and publishing in higher-impact journals beyond regional scopes. Additionally, while five books have been authored, the addition of patents or translational innovations could enhance his profile in the realm of research commercialization and practical medical technologies.

Education :

Dr. Zhi Guo holds a strong academic background in clinical medicine and medical research. He earned his Bachelor’s degree in Medicine from Tongji Medical College in 2000. Subsequently, he pursued his postgraduate medical studies at the Third Military Medical University, completing it in 2007. His academic journey culminated with the attainment of a Doctor of Medicine (MD) degree from Wuhan University of Science and Technology. His education laid a strong foundation in hematology and clinical research methodologies. Each step in his educational path was marked by an emphasis on academic rigor and clinical competence, preparing him for a leadership role in medical science and hematologic research. His multidisciplinary background has enabled him to integrate clinical insights with advanced laboratory-based innovations, contributing to national-level guidelines and the development of cutting-edge CAR-T cell therapies and transplantation techniques.

Experience :

Dr. Zhi Guo brings nearly 25 years of clinical, academic, and leadership experience in the field of hematology. He began his professional journey at the PLA Army General Hospital, where he served from 2000 to 2018. During this period, he honed his clinical and procedural expertise in managing complex hematologic disorders. Since 2018, he has been leading the Department of Hematology at Huazhong University of Science and Technology Union Shenzhen Hospital as Director, Academic Leader, and Chief Physician. His rich experience includes more than 1,300 hematopoietic stem cell transplantations, encompassing autologous, allogeneic, and CAR-T integrated therapies. His leadership extends beyond clinical care, as he also mentors postgraduate medical students and leads multiple national and institutional research projects. Dr. Guo’s practical experience is balanced with his strategic contributions to medical consensus formulation and research-driven policy initiatives in cancer and immune-hematological disorders.

Research Focus :

Dr. Zhi Guo’s research centers on hematologic malignancies and hematopoietic stem cell transplantation, particularly the integration of cellular immunotherapy such as CAR-T cell treatments. His recent work includes pioneering anti-CD19, anti-CD7, and anti-BCMA CAR-T therapies for lymphomas and leukemias. Additionally, he has investigated the interplay between microbiota and immune modulation in transplantation, highlighting the role of gut and oral microbiomes in patient outcomes. His contributions have influenced the development of clinical guidelines for microbiota-related diagnostics and treatments in oncology. With more than 10 high-impact journal publications and ongoing projects in translational medicine, Dr. Guo’s work combines laboratory innovation with patient-centered applications. He has also authored expert consensus documents and national guidelines, helping shape China’s hematology and transplantation protocols. His commitment to interdisciplinary collaboration, clinical innovation, and translational research underscores his leading role in advancing modern hematology.

Publications Top Notes:

  1. 🧬 In vitro validation of anti-CD19 CAR-T cells with LSD1 shRNA for DLBCL – Front Immunol, 2025

  2. 🩸 Case of T-ALL treated with chemo + anti-CD7 CAR-T (retroviral vector) – Front Immunol, 2025

  3. 👶 Shaping oral/intestinal microbiota & immunity in first 1,000 days of life – Front Pediatr, 2025

  4. 💩 Fecal microbiota transplantation in acute GVHD treatment – J Cancer Res Ther, 2024

  5. 🔬 Chinese consensus on gut microecology lab standards – Exp Ther Med, 2024

  6. 🧪 2024 Chinese guidelines for intestinal microecology in cancer – J Cancer Res Ther, 2024

  7. 🧫 First MM case treated with ASCT + anti-BCMA CAR-T (retrovirus) – Heliyon, 2024

  8. 🧾 Rapid response in relapsed FL to anti-CD19 CAR-T with CMV – Int Immunopharmacol, 2024

  9. 🦷 Prognostic impact of oral microbiome in cancer survival – meta-analysis – Syst Rev, 2024

  10. 🧍‍⚕️ Expert consensus on gut microbiome & hematopoietic stem cell transplantation – Clin Transplant, 2024

Conclusion:

In conclusion, Dr. Zhi Guo is highly suitable for the Best Researcher Award. His combination of clinical excellence, academic leadership, and impactful research in hematology and stem cell transplantation positions him among the top contributors in this specialized field. With ongoing research in CAR-T cell therapies, microbiota influence on transplantation, and immuno-oncology, Dr. Guo continues to shape the future of hematologic cancer care. Recognizing his contributions with this award would be both fitting and encouraging for continued innovation in this vital area of medicine.

 

Philippe Menasché | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Philippe Menasché | Stem Cell Research | Best Researcher Award

Prof. Philippe Menasché, AP-HP, France

Prof. Philippe Menasché, born on August 10, 1950, is a pioneering French cardiovascular surgeon and regenerative medicine researcher. Renowned globally for his work in cell therapy and heart failure, he performed the world’s first fetal stem cell transplantation in a human heart. With over four decades in medicine, he has blended surgical excellence with translational research, bridging the gap between bench and bedside. A professor since 1988, his leadership spans multiple roles—from senior hospital surgeon to director of major research teams at INSERM and the Carpentier Foundation. He has served as scientific advisor to health authorities and remains an active contributor to high-impact publications and international collaborations. A recipient of prestigious honors such as the Prix Galien and the Earl Bakken Award, Prof. Menasché continues to shape the future of cardiovascular regenerative therapy.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Pioneering Clinical Innovation

    • Performed the first-in-man fetal stem cell transplantation for cardiac repair.

    • Led translational research turning basic stem cell science into clinical applications.

  2. Extensive Academic and Research Leadership

    • Over four decades of experience as a cardiovascular surgeon and academic leader.

    • Directed major units at INSERM, Carpentier Foundation, and Paris Hospitals.

  3. Global Recognition and Awards

    • Recipient of highly prestigious scientific prizes such as the Prix Galien (2016) and Earl Bakken Award (2011).

    • Recognized by top French and international medical societies.

  4. Recent and Relevant Research Impact

    • Active contributor to multicenter trials including ISCHEMIA, STROMA-CoV-2, and TRAUMACELL.

    • Publications in high-impact journals on cardiac regeneration, cell therapy, and stem cell-derived secretomes.

  5. Leadership in Science Policy and Ethics

    • President of the Medical and Scientific Council at France’s Agency of Biomedicine.

    • Advisor to the French Minister of Health (2005–2007), influencing national bioethics and translational policy.

⚠️ Areas for Improvement:

  1. Broader International Integration

    • While internationally recognized, deeper ongoing collaboration with North American and Asian biomedical consortia could further elevate global influence.

    • The upcoming visiting professorship at Columbia University (2025) is a strong step in this direction.

  2. Integration of AI & Digital Health

    • Limited evidence of work in AI-guided regenerative medicine, machine learning in cardiac diagnostics, or digital health integration in therapeutic development.

    • These areas represent major future growth potential in cardiac care.

  3. Mentorship Visibility

    • While his scientific contributions are vast, greater emphasis on training and mentoring the next generation of clinician-scientists would bolster his legacy.

📚 Education:

Prof. Menasché’s academic foundation is rooted in two pillars of French higher education. He earned his Doctor of Medicine (MD) from the Faculté de Médecine de Paris in 1979, graduating with honors, including the coveted Internship Golden Medal. He then pursued deeper inquiry into biomedical science, culminating in a Doctorate in Science (PhD) from Université Paris-Orsay in 1987. His dual training in clinical medicine and scientific research provided the ideal springboard for a career that integrates patient care with innovation. In 1988, he became a Professor of Thoracic and Cardiovascular Surgery, reflecting his command of both technical skill and academic leadership. His scholarly progression has also led to visiting roles abroad, including a forthcoming appointment as Visiting Professor in Biomedical Engineering at Columbia University in 2025. This cross-disciplinary education empowers his unique contribution to both surgical practice and regenerative cardiovascular therapies.

🏥 Experience:

Prof. Menasché began his medical journey in 1973 as an intern in Paris hospitals, ascending to Senior Staff Surgeon in 1988—a position he still holds. From 1995 to 2007, he served as Director of Research at the Surgical School of the Greater Paris Academic Hospitals. His research leadership extended to INSERM, where he directed Unit U633 and co-led regenerative therapy teams. He headed the Laboratory of Biosurgical Research at the Carpentier Foundation from 2002 to 2018. In parallel, he has played influential roles on regulatory and advisory boards, including as President of the Medical and Scientific Council of France’s Agency of Biomedicine. A dedicated member of multiple medical and scientific societies, Prof. Menasché has edited prestigious journals and contributed to over a dozen major clinical trials and collaborative studies. His experience combines clinical excellence, institutional leadership, and innovative research in heart failure and cell therapy.

🧬 Research Focus:

Prof. Menasché’s research is centered on regenerative medicine for cardiovascular diseases, particularly using stem cells and secretomes to repair damaged heart tissue post-myocardial infarction. His team explores therapeutic strategies involving pluripotent stem cell-derived cardiomyocytes, mesenchymal stromal cells, and extracellular vesicles to promote myocardial regeneration and immune modulation. He has led pioneering first-in-human trials, including the use of cell-derived secretomes in heart failure patients. His investigations bridge fundamental science with translational application, often conducted in multicenter randomized controlled trials. His work also intersects with neurological conditions, such as traumatic brain injury, using cell-based therapies to address neuroinflammation. Prof. Menasché is also involved in evaluating the safety and efficacy of stem cell-based interventions in ARDS, including COVID-19-associated cases. A central member of the European Society of Cardiology’s regenerative medicine group, he is advancing personalized and precise treatments for heart failure through novel biologics and bioengineering tools.

📄 Publications Top Notes:

  1. 🫀 Revitalizing the heart: strategies and tools for cardiomyocyte regeneration post-myocardial infarction

  2. 💉 Trials and tribulations of cell therapy for heart failure: an update on ongoing trials

  3. 🫀📊 Evaluating the Appropriate Use Criteria for Coronary Revascularization in Stable Ischemic Heart Disease Using Randomized Data From the ISCHEMIA Trial

  4. 🧠🧪 Effects of intravascular administration of mesenchymal stromal cells…after traumatic brain injury (TRAUMACELL)

  5. 💓🧫 Relationship Between Severity of Ischemia and Coronary Artery Disease for Different Stress Test Modalities in the ISCHEMIA Trial

  6. 🦠🫁 Treatment of COVID-19-associated ARDS with umbilical cord-derived mesenchymal stromal cells (STROMA-CoV-2)

  7. 🧬💗 Head-to-head comparison of relevant cell sources of small extracellular vesicles for cardiac repair

  8. 🫀💉 First-in-man use of a cardiovascular cell-derived secretome in heart failure – Case report

  9. 🧬🫀 Human PSC-derived cardiac cells and their products: therapies for cardiac repair

  10. 🫀🫄 Impact of Complete Revascularization in the ISCHEMIA Trial

📝 Conclusion:

Prof. Philippe Menasché is exceptionally qualified for the Best Researcher Award. His groundbreaking work in cardiac regeneration, commitment to translational medicine, and lasting contributions to surgical science and healthcare policy make him a uniquely impactful figure. His track record is not only defined by scientific innovation but also by societal relevance, particularly in addressing heart failure—a leading global health burden.

Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Sibel Elif Gultekin | Stem Cell Research | Best Researcher Award

Prof. Dr. Sibel Elif Gultekin, Gazi University Faculty of Dentistry, Turkey

Prof. Dr. Sibel Elif Gültekin is a renowned academic and clinician in Oral Pathology and Periodontology at Gazi University Faculty of Dentistry, Türkiye. With over two decades of experience, she has significantly advanced molecular understanding of odontogenic tumors, HPV-induced oral lesions, and periodontal regeneration. Holding both DDS and Ph.D. degrees, she has led her department as Chair for 10 years and contributed globally as a visiting researcher and advisor. Her collaborations with institutions like the University of Cologne and UCSF reflect her international impact. She has published extensively in high-impact journals, authored books, and mentored numerous young researchers. Her dedication has been recognized through editorial appointments and professional society memberships. Prof. Gültekin’s translational research bridges pathology and clinical dentistry, making her a pioneer in the diagnosis and treatment of oral diseases.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Dual Specialization & Academic Leadership: Prof. Gültekin’s rare dual Ph.D. in Oral Pathology and Periodontology, along with her decade-long leadership as department chair, highlights deep academic and organizational expertise.

  2. High Research Output & Impact: With 96 publications, 50+ research projects, and citations exceeding 1300 (Google Scholar), her scholarly productivity and influence are clear. Her h-index across databases (14–17) confirms consistent academic contribution.

  3. Global Collaborations: Active collaborations with international centers like UCSF and University of Cologne underscore her role in global scientific advancement.

  4. Innovative Research Areas: She works at the forefront of molecular oncology, focusing on HPV-associated oral cancers, odontogenic tumors, and biomarkers like P16, VIM3, and PDCD4.

  5. Educational & Editorial Leadership: Served on scientific and editorial boards, symposiums, and advisory panels; she also authored 2 academic books and guided national congresses.

  6. Professional Societies: Active member of multiple esteemed societies (IAOP, ESP, EHNS, IADR), reflecting recognition in the international scientific community.

⚙️ Areas for Improvement:

  1. Clinical Translation Scaling: While her biomarker discoveries are notable, increasing efforts to lead translational clinical trials could accelerate therapeutic application.

  2. Policy Advocacy: Engaging more in international oral health policy or WHO-affiliated programs could amplify her impact beyond academia.

  3. Mentorship on Global Scale: Expanding formal international mentorship programs or fellowships could further cement her influence and legacy.

🎓 Education:

Prof. Dr. Sibel Elif Gültekin holds both DDS and Ph.D. degrees, specializing in Oral Pathology and Periodontology. She completed her undergraduate dental studies at Gazi University Faculty of Dentistry, where she later pursued her doctoral studies. Her academic training extended beyond Türkiye through international fellowships and research placements, including the prestigious Department of Medicine and Stomatology at the University of California San Francisco (UCSF) and the Institute for Pathology at the University of Cologne. Her educational journey is marked by an interdisciplinary approach, blending basic sciences and clinical applications. These robust academic foundations have positioned her as a global expert in oral cancer biomarkers, regenerative periodontology, and molecular pathology, nurturing future dentists and researchers through an integrative, evidence-based curriculum and global research exposure.

💼 Experience:

Prof. Dr. Gültekin has over 25 years of experience in dentistry, oral pathology, and periodontology. She has served as Professor and Chair of the Department of Oral Pathology at Gazi University, shaping both academic curricula and national diagnostic standards. Internationally, she collaborated with UCSF and the University of Cologne on pioneering projects in oral cancer and HPV research. Her clinical and academic background spans over 50 funded research projects, with 96 published papers in prestigious journals indexed by SCI, Scopus, and PubMed. She has contributed to oral health policy through editorial and advisory roles, including at journals like Journal of Oral Health Frontiers. Her expertise has guided scientific boards and symposia in Türkiye and beyond, particularly in head and neck pathology. She remains a sought-after consultant and reviewer, advocating for personalized medicine and molecular diagnostics in oral health.

🔬 Research Focus:

Prof. Dr. Sibel Elif Gültekin’s research centers on the molecular mechanisms of oral diseases, particularly odontogenic tumors, oral epithelial dysplasia, and HPV-induced carcinomas. She has made key contributions in identifying biomarkers such as P16, PDCD4, VIM3, and CD8+ T-cell infiltrates, enhancing early diagnosis and prognosis of oral and oropharyngeal cancers. Her research also explores microsatellite instability and loss of heterozygosity in oral squamous cell carcinoma. Additionally, she has contributed to periodontal tissue regeneration studies and the development of personalized therapeutic strategies. With over 1,300 citations and an h-index of 17 on Google Scholar, her impactful work bridges molecular science and clinical application. Collaborating with global experts in pathology, oncology, and molecular biology, Prof. Gültekin’s research not only contributes to academic literature but also informs clinical protocols and treatment pathways in modern dentistry and oral oncology.

📚 Publications Top Notes:

  • 🧬 Microsatellite Instability and Loss of Heterozygosity as Prognostic Markers in Oral Squamous Cell Carcinoma (Genes, Chromosomes and Cancer, 2024)

  • 🧪 Efficiency of B-RAF-/MEK-inhibitors in B-RAF Mutated Ameloblastoma: Case Report and Review (Heliyon, 2023)

  • 🦷 Kişiselleştirilmiş Diş Hekimliği (ADO Klinik Bilimler Dergisi, 2023)

  • 🔍 Apoptosis Related PDCD4: Promising Novel Biomarker for Early Detection of Oral Cancer (ADO Klinik Bilimler Dergisi, 2022)

  • 🛡️ PD-L1 Expression and High CD8+ Lymphocyte Infiltrate Predict Outcome in Oropharyngeal SCC (International Journal of Molecular Sciences, 2020)

🧾 Conclusion:

Prof. Dr. Sibel Elif Gültekin is a highly deserving nominee for the Best Researcher Award. Her pioneering contributions in oral pathology, particularly in molecular diagnostics and HPV-related oral oncology, place her at the forefront of dental research. Her exceptional academic record, leadership, and dedication to collaborative and translational science make her a standout candidate who embodies the spirit of innovation, mentorship, and global impact.

Yang Gao | Cell Differentiation Processes | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Yang Gao | Cell Differentiation Processes | Best Researcher Award

Prof. Dr. Yang Gao , The Sixth Affiliated Hospital of Harbin Medical University , China

Professor Yang Gao is the Chief Physician and Director of the Critical Care Medicine Department at The Sixth Affiliated Hospital of Harbin Medical University, China. He is a respected academic and clinical expert in critical care, serving also as a Doctoral Supervisor. With over two decades of frontline medical experience, Professor Gao has led nine major research projects and published 33 SCI-indexed papers, amassing a citation index of 313 and an overall impact factor of 94.493. He holds prominent roles in national and provincial academic societies, contributing to innovations in sepsis, AKI, and renal replacement therapy (RRT). His dedication to clinical advancement is matched by his commitment to medical education and research. Recognized for his pioneering work in critical care medicine, he has received patents and published multiple medical textbooks. His leadership, extensive research contributions, and continued impact on critical care practices make him a strong candidate for the Best Researcher Award.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. Extensive Clinical & Research Expertise: With over two decades in frontline critical care, Professor Gao combines clinical acumen with deep research insight, particularly in sepsis-associated acute kidney injury (AKI) and continuous renal replacement therapy (RRT).

  2. High-Impact Research Output: He has authored 33 SCI-indexed publications with a cumulative impact factor of 94.493 and over 313 citations, reflecting global recognition and academic influence.

  3. Research Leadership: Professor Gao has successfully led 9 major research projects, funded at national and provincial levels, demonstrating his capability in resource management, innovation, and scientific leadership.

  4. Academic Contributions: His dual role as a doctoral supervisor and textbook author, along with a granted utility model patent, showcases a broad contribution to both research and education.

  5. Professional Recognition: Active in numerous national societies and editorial boards, he maintains a strong presence in shaping critical care medicine in China.

🔍 Areas for Improvement:

  • International Collaboration: While his national involvement is robust, fostering more international research partnerships would further expand the global relevance of his work.

  • Industry Engagement: Engagement with biotechnology or medical device industries could enhance translational applications of his findings in clinical settings.

🎓 Education:

Professor Yang Gao obtained his medical degree and advanced postgraduate training from institutions affiliated with Harbin Medical University, one of China’s leading medical schools. His rigorous academic journey included specialized training in critical care medicine, advanced life support technologies, and clinical research methodology. During his doctoral studies, he focused on critical illness mechanisms, with an emphasis on sepsis-associated acute kidney injury (AKI). He has consistently updated his expertise through postdoctoral fellowships and high-level academic forums. Further professional development was supported by the Heilongjiang Province Postdoctoral Start-up Fund, enhancing his academic and research foundation. Professor Gao’s medical education has equipped him with both theoretical knowledge and practical competence to lead complex multidisciplinary care units and mentor future medical scientists. His dual role as a clinical expert and academic leader reflects a strong commitment to translational medicine and healthcare innovation in China.

🏥 Experience:

With over 20 years of hands-on clinical experience, Professor Yang Gao has emerged as a leader in critical care medicine in China. Since 2003, he has been managing critically ill patients, mastering life-saving interventions such as non-invasive/invasive ventilation, blood purification, and continuous renal replacement therapy (CRRT). He is the Director of the Critical Care Medicine Department at The Sixth Affiliated Hospital of Harbin Medical University and holds teaching and supervisory roles for doctoral students. His experience spans both frontline medical services and academic research, with a portfolio that includes 33 SCI publications, textbook authorship, and national-level project leadership. In addition to clinical work, he contributes to national guidelines and policy-making through roles in multiple medical societies and editorial boards. Recognized for both his clinical excellence and scientific insight, Professor Gao has been instrumental in improving patient care outcomes and advancing the understanding of critical care physiology.

🔬 Research Focus:

Professor Yang Gao’s research is concentrated on the pathophysiology and treatment of sepsis-associated acute kidney injury (AKI) and the optimal application of continuous renal replacement therapy (CRRT). He has led and collaborated on key national and provincial projects, investigating biomarkers, timing of intervention, and therapeutic mechanisms in critically ill patients. His innovative work includes molecular-level studies on sepsis progression and clinical trials to determine best practices in critical care. He is also exploring analgesia and sedation protocols in ICU settings, as part of national key research programs. His published SCI research, with an impressive cumulative impact factor nearing 95, reflects his dedication to translating science into improved patient care. Through systemic analysis and advanced diagnostic models, Professor Gao is developing new frameworks for early identification of organ dysfunction, particularly kidney injury, in intensive care settings. His research continues to influence treatment protocols and critical care education across China.

📚 Publications Top Notes:

  1. 🧪 Magnetic properties and protective activity on burn disease by regulating mutated fibroblasts – J. Solid State Chem (2021)

  2. 🧫 Role of IL-10 and TNF-α in Sepsis-Induced AKI – Front. Immunol

  3. 🩺 Timing of CRRT in Septic Shock Patients with AKI – Crit Care Med

  4. 🔍 Identification of Biomarkers for Sepsis Progression in ICU – J Intensive Care

  5. 🧠 Neurological Outcomes in ICU Patients Receiving Sedation – Brain Res

  6. 🦠 MicroRNA Profiling in Sepsis-Induced Kidney Damage – Mol Med Rep

  7. 🧬 Effects of Early CRRT on Inflammatory Mediators – Cytokine

  8. 🧴 Pharmacokinetics of Antibiotics in CRRT Patients – Ther Drug Monit

  9. 🧍‍♂️ Prognostic Value of Serum NGAL in AKI Patients – Am J Nephrol

  10. 💉 Comparison of Hemoperfusion and Hemodialysis in Toxin Clearance – Blood Purif

🧾 Conclusion:

Professor Yang Gao stands out as a pioneering figure in critical care research, blending clinical innovation with scholarly rigor. His sustained contributions to understanding and treating sepsis and AKI, along with his strong academic leadership, make him eminently suitable for the Best Researcher Award. Recognizing his work will not only honor his achievements but also encourage continued excellence and international collaboration in life-saving medical science.